EFFICACY OF SUBSEQUENT CHEMOTHERAPY FOLLOWED BY PARP INHIBITOR MAINTENANCE IN PATIENTS WITH ADVANCED OVARIAN CANCER IN THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL

被引：2

作者：

Marth, Christian ^{[1
,2
]}

Mouret-Reynier, Marie-Ange ^{[3
,4
]}

Lorusso, Domenica ^{[5
,6
,7
]}

Cropet, Claire ^{[8
,9
]}

Harter, Philipp ^{[10
,11
]}

Guerra, Eva ^{[12
,13
]}

Matsumoto, Takashi ^{[14
,15
]}

Vergote, Ignace ^{[16
,17
]}

Colombo, Nicoletta ^{[18
,19
,20
]}

Maenpaa, Johanna ^{[21
,22
]}

Lebreton, Coriolan ^{[23
,24
]}

De Gregorio, Nikolaus ^{[25
,26
,27
,28
]}

Mosconi, Anna Maria ^{[29
,30
]}

Rubio, Maria Jesus ^{[31
,32
]}

Bourgeois, Hugues ^{[33
,34
]}

Fasching, Peter A. ^{[35
,36
]}

Hardy-Bessard, Anne-Claire ^{[37
,38
]}

Denschlag, Dominik ^{[39
,40
]}

Pujade-Lauraine, Eric ^{[41
,42
]}

Ray-Coquard, Isabelle ^{[8
,9
]}

机构：

[1] Med Univ Innsbruck, Dept Obstet & Gynaecol, Innsbruck, Austria

[2] AGO Austria, Innsbruck, Austria

[3] Ctr Jean Perrin, Clermont Ferrand, France

[4] GINECO, Clermont Ferrand, France

[5] Ist Tumori Milano Fdn Policlin Univ A Gemelli IRC, Rome, Italy

[6] Univ Cattolica Sacro Cuore, Rome, Italy

[7] MITO, Rome, Italy

[8] Ctr Leon Berard, Lyon, France

[9] GINECO, Lyon, France

[10] Kliniken Essen Mitte, Essen, Germany

[11] AGO, Essen, Germany

[12] Hosp Univ Ramon & Cajal, Madrid, Spain

[13] GEICO, Madrid, Spain

[14] Ehime Univ Hosp, Toon, Japan

[15] GOTIC, Toon, Japan

[16] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

[17] BGOG, Leuven, Belgium

[18] Univ Milano Bicocca, Milan, Italy

[19] European Inst Oncol IRCCS, Milan, Italy

[20] MANGO, Milan, Italy

[21] Tampere Univ Hosp, Tampere, Finland

[22] NSGO, Tampere, Finland

[23] Inst Bergonie, Bordeaux, France

[24] GINECO, Bordeaux, France

[25] Univ Klinikum Ulm, Klin Frauenheilkunde & Geburtshilfe, Ulm, Germany

[26] AGO, Ulm, Germany

[27] SLK Kliniken Heilbronn GmbH, Frauenklinik, Heilbronn, Germany

[28] AGO, Heilbronn, Germany

[29] SC Oncol Med Osp S Maria Misericordia AO Perugia, Perugia, Italy

[30] MITO, Perugia, Italy

[31] Hosp Reina Sofia, Cordoba, Spain

[32] GEICO, Cordoba, Spain

[33] Ctr Jean Bernard, Clin Victor Hugo, Le Mans, France

[34] GINECO, Le Mans, France

[35] Univ Frauen Klinik Erlangen, Erlangen, Germany

[36] AGO, Erlangen, Germany

[37] Ctr CARIO, HPCA, Plerin Sur Mer, France

[38] GINECO, Plerin Sur Mer, France

[39] Hochtaunus Kliniken, Bad Homburg, Germany

[40] AGO, Bad Homburg, Germany

[41] ARCAGY Res, Paris, France

[42] GINECO, Paris, France

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷

关键词：

D O I：

10.1136/ijgc-2023-ESGO.30

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

528

引用

页码：A21 / A21

页数：1

共 50 条

[41] OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer
Pujade-Lauraine, E.
Colombo, N.
Glasspool, R.
Asselain, B.
Huzarski, T.
Korach, J.
Marme, F.
Mirza, M. R.
Redondo, A.
Scambia, G.
Blakeley, C.
Milner, A.
Selle, F.
Vergote, I.
ANNALS OF ONCOLOGY, 2017, 28
[42] EFFICACY OF MAINTENANCE OLAPARIB PLUS BEVACIZUMAB BY BIOMARKER STATUS IN CLINICAL HIGHER- AND LOWER-RISK PATIENTS WITH NEWLY DIAGNOSED, ADVANCED OVARIAN CANCER IN THE PAOLA-1 TRIAL
Harter, P.
Petran, D.
Scambia, G.
Ortega, E.
Tsibulak, I.
Nagao, S.
Vergote, I.
Meunier, J.
Priou, F.
Sverdlin, R.
Milenkova, T.
Ray-Coquard, I.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A13 - A14
[43] Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)
Penson, R.
Kaminsky-Forrett, M-C.
Ledermann, J.
Brown, C.
Plante, M.
Korach, J.
Huzarski, T.
Lista, A. Gomez de Liano
Pisano, C.
Friedlander, M.
Colombo, N.
Gropp-Meier, M.
Nakai, H.
Sonke, G. S.
Kim, J-W.
Vergote, I.
Allen, A.
Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2017, 28
[44] The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
Zhu, Youwen
Liu, Kun
Cao, Hui
Zhu, Hong
JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
[45] The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
Youwen Zhu
Kun Liu
Hui Cao
Hong Zhu
Journal of Ovarian Research, 16
[46] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial
Grimm, C.
Cropet, C.
Ray-Coquard, I.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 19 - 19
[47] ENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.
Mirza, M.
Berek, J. S.
Vergote, I.
Wenham, R. M.
Del Campo, J. M.
Oza, A. M.
Mahner, S.
Monk, B. J.
Fabbro, M.
Ledermann, J. A.
Marth, C.
Bruchim, I.
Katsaros, D.
Lorusso, D.
Malander, S.
Dorum, A.
Agarwal, S.
Martell, R. E.
Matulonis, U.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 33 - 34
[48] ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer
Fujiwara, K.
Vergote, I. B.
Sehouli, J.
Salutari, V.
Zola, P.
Madry, R.
Wenham, R. M.
Korach, J.
Pautier, P.
Cibula, D.
Lheureux, S.
Hasegawa, K.
Kim, B-G.
Lai, C-H.
Gonzalez-Martinez, A.
Liu, Q.
Keefe, S. M.
Puglisi, M.
Topuz, S.
ANNALS OF ONCOLOGY, 2019, 30
[49] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
Lorusso, Domenica
Lotz, Jean-Pierre
Harter, Philipp
Cropet, Claire
Perez, Maria Jesus Rubio
Schauer, Christian
Matsumoto, Takashi
Vergote, Ignace
Colombo, Nicoletta
Noettrup, Trine Jakobi
Bourgeois, Hugues Pierre
Schnelzer, Andreas
Pignata, Sandre
Garcia, Yolanda
Provansal, Magali
Hanker, Lars Christian
Berton, Dominique
Bauerschlag, Dirk
Joly, Florence
Ray-Coquard, Isabelle Laure
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Colombo, N.
Gantzer, J.
Ataseven, B.
Cropet, C.
Scambia, G.
Herrero, A.
Sevelda, P.
Kobayashi, H.
Vuylsteke, P.
Mirza, M. R.
Priou, F.
Buderath, P.
Pisano, C.
Lainez, N.
Guillemet, C.
Burges, A.
Sverdlin, R.
El-Balat, A.
Raban, N.
Ray-Coquard, I. L.
ANNALS OF ONCOLOGY, 2020, 31 : S614 - S614

← 1 2 3 4 5 →